<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for advanced anal squamous cell cancer: Weekly paclitaxel plus every-three-week carboplatin&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for advanced anal squamous cell cancer: Weekly paclitaxel plus every-three-week carboplatin<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for advanced anal squamous cell cancer: Weekly paclitaxel plus every-three-week carboplatin<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup> <colgroup width="40%"></colgroup> <colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"> <strong>Cycle length:</strong> 28 days.<br/> <strong>Duration of therapy:</strong> Until disease progression or unacceptable toxicity. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Mix in 250 mL NS or D5W* and administer over 1 hour.<sup>¶</sup></td> <td>Days 1, 8, and 15</td> </tr> <tr class="divider_bottom"> <td>Carboplatin</td> <td>AUC<sup>Δ</sup> = 5 mg/mL per min IV</td> <td>Dilute in 250 mL NS or D5W* and administer over 30 minutes (administer after the completion of the paclitaxel infusion).</td> <td>Day 1</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>MODERATE on day 1;<br/> LOW on days 8 and 15.<sup>◊</sup></li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Premedicate with a glucocorticoid and H1 and H2 receptor blockers prior to paclitaxel administration. Patients who receive paclitaxel on a weekly basis have the potential to receive substantial doses of dexamethasone; ongoing glucocorticoid treatment is unnecessary in most. One approach to minimizing glucocorticoid use is to administer a lower dexamethasone dose (10 mg IV) with an H1 and H2 receptor blocker 30 minutes prior to the first administration of weekly paclitaxel. Glucocorticoid doses can then be safely tapered by weekly 2-mg decrements in patients without infusion reactions, and eventually discontinued.<sup>[2,3]</sup></li> <li>Carboplatin is also associated with infusion reactions. However, they usually occur after at least six cycles, and no specific premedication regimen is recommended.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Carboplatin is an irritant. Paclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on "Extravasation injury from chemotherapy and other non-antineoplastic vesicants".</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with G-CSF not recommended. The trial reported a 5% rate of febrile neutropenia and 29% grade 3 or 4 neutropenia.<sup>[1]</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.<sup>Δ</sup><sup>[4]</sup> A lower starting dose of paclitaxel may be needed in patients with liver impairment.<sup>[5]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and dosing of anticancer agents in adults.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential on each treatment day.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Serum electrolytes and liver and renal function tests prior to each new treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess changes in neurologic function prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for infusion reactions and extravasation.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity<sup>[1]</sup>:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>For a new cycle of therapy, delay treatment until the ANC is ≥1500/microL and the platelet count is ≥100,000/microL.<sup>[1]</sup> If hematologic recovery requires &gt;7 days and the day 29 ANC is &lt;1000/microL, reduce day 1 carboplatin by 1 AUC<sup>Δ</sup> unit (ie, from 5 to 4 mg/mL per min). If hematologic recovery requires &gt;7 days and the day 1 platelet count is &lt;50,000/microL, reduce day 1 paclitaxel from 80 to 70 mg/m<sup>2</sup>. For the second occurrence, reduce carboplatin by an additional AUC<sup>Δ</sup> unit, and reduce paclitaxel to 60 mg/m<sup>2</sup>.</li> <li>Omit the day 8 and 15 doses of paclitaxel if any of the following occurs within 24 hours prior to administration: ANC &lt;1000/microL, platelets &lt;75,000/microL, or hemoglobin ≤8 g/dL. Omitted doses are not made up. If the ANC was &lt;1000/microL or the platelet count was &lt;75,000/microL on day 8 or 15, reduce carboplatin dose for the next cycle by 1 AUC<sup>Δ</sup> unit. If the platelet count was &lt;50,000/microL on day 8 or 15, reduce paclitaxel dose for the next cycle from 80 mg/m<sup>2</sup> to 70 mg/m<sup>2</sup>. For the second occurrence, reduce paclitaxel to 60 mg/m<sup>2</sup>.</li> <li>If day 15 paclitaxel administration has been omitted due to hematologic toxicity and the criteria for treatment continuation on day 1 of the next cycle are not met, reduce day 1 carboplatin by 1 AUC<sup>Δ</sup> unit, and reduce day 1 paclitaxel by 1 dose level.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurologic toxicity</strong></td> <td colspan="3"> <ul> <li>For grade 2 or worse sensory or motor peripheral neuropathy, interrupt therapy until resolved to ≤grade 1; on recovery, reduce paclitaxel dose from 80 to 70 mg/m<sup>2</sup> for subsequent courses.<sup>[1]</sup> For delay in recovery &gt;2 weeks, or any grade 3 or worse neuropathy, discontinue paclitaxel.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose.<sup>[4]</sup> The development of grade 2 or worse elevations in AST, ALT, ALP, or bilirubin requires reduction in paclitaxel dose from 80 to 70 mg/m<sup>2</sup> after recovery to ≤grade 1.<sup>[1]</sup></li> <li>Refer to UpToDate topics on dosing of anticancer agents in adults and chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="3"> <ul> <li>For grade 3 or worse diarrhea on the day of treatment, hold paclitaxel. Once resolved to ≤grade 1, reduce dose from 80 to 70 mg/m<sup>2</sup> for future cycles.<sup>[1]</sup></li> <li>For grade ≥3 mucositis, delay treatment until resolved to ≤grade 1, and reduce paclitaxel from 80 to 70 mg/m<sup>2</sup>.<sup>[1]</sup> For second occurrence, or if grade 3 or worse mucositis persists for more than 2 weeks, discontinue paclitaxel.</li> <li>For all other nonhematologic toxicities grade 3 or worse (except alopecia, constipation, nausea, and infusion reactions), hold therapy until resolved to ≤grade 1.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; AUC: area under the concentration × time curve; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count; ANC: absolute neutrophil count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; GFR: glomerular filtration rate; NCCN: National Comprehensive Cancer Network; ASCO: American Society of Clinical Oncology; MASCC: Multinational Association for Supportive Care in Cancer.<br/>* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>¶ Paclitaxel can be administered at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br/>Δ AUC is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If an estimated GFR based upon measured serum creatinine is used in the Calvert equation, and renal function is normal, clinicians should consider capping the GFR at 125 mL/min, at least for the first dose. This recommendation does not apply if the GFR is directly measured. Refer to UpToDate topic on "Dosing of anticancer agents in adults".<br/><font class="lozenge">◊</font> Consensus-based guidelines from the NCCN classify higher carboplatin doses (AUC<sup>Δ</sup> &gt;4) as highly emetogenic; by contrast, ASCO and the MASCC guidelines consider all carboplatin doses to be moderately emetogenic. Although many institutions classify carboplatin-containing regimens as moderately emetogenic, a benefit for adding a neurokinin 1 receptor antagonist on day 1 has been shown in many studies; additional prophylaxis beyond day 1 for delayed emesis is not needed for most patients. Refer to UpToDate topic on "Prevention and treatment of chemotherapy-induced nausea and vomiting in adults".</div><div class="graphic_reference">References: 

<ol>
<li>Rao S, et al. J Clin Oncol 2020; 38: 2510.</li>
<li>Berger MJ, et al. Support Care Cancer 2015; 23:2019.</li>
<li>Parinyanitikul N, et al. Support Care Cancer 2018; 26:2471.</li>
<li>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 17, 2020).</li>
<li>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 17, 2020).</li></ol></div><div id="graphicVersion">Graphic 130564 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
